drugset
drugset / Trial / NCT06834529

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

NCT06834529 ↗

Phase 1/2 Recruiting 20 enrolled Affiliated Hospital to Academy of Military Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.

Timeline

Start
2025-01-20
Primary completion
2027-01-31
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified 500000 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 1e+06 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 2e+06 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous

Indications

B-cell neoplasm